BRAF ,NRASandC-KITAdvanced Melanoma: Clinico-pathological Features, Targeted-Therapy Strategies and Survival
Articolo
Data di Pubblicazione:
2017
Citazione:
BRAF
,NRASandC-KITAdvanced Melanoma: Clinico-pathological Features, Targeted-Therapy Strategies and Survival / Ponti, Giovanni; Manfredini, Marco; Greco, Stefano; Pellacani, Giovanni; Depenni, Roberta; Tomasi, Aldo; Maccaferri, Monia; Cascinu, Stefano. - In: ANTICANCER RESEARCH. - ISSN 0250-7005. - 37:12(2017), pp. 7043-7048. [10.21873/anticanres.12175]
Abstract:
The mutational status of stage III and IV melanomas should be recognized in order to allow for targeted therapies. The aim of our study was the characterization of BRAF, NRAS and C-KIT melanoma patients, in order to define their optimal management.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
Advanced melanoma; BRAF; NRAS and C-KIT; survival; targeted therapies; Aged; Antineoplastic Agents; Female; GTP Phosphohydrolases; Humans; Kaplan-Meier Estimate; Male; Melanoma; Membrane Proteins; Middle Aged; Molecular Targeted Therapy; Prognosis; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-kit; Skin Neoplasms; Mutation
Elenco autori:
Ponti, Giovanni; Manfredini, Marco; Greco, Stefano; Pellacani, Giovanni; Depenni, Roberta; Tomasi, Aldo; Maccaferri, Monia; Cascinu, Stefano
Link alla scheda completa:
Pubblicato in: